Drug Trial Radar · NCT07925619
Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Feb 1, 2027
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Pharmosa Biopharm Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is designed to evaluate the efficacy and safety of L608 compared to placebo in patients with SSc-DU.
Conditions
- Systemic Sclerosis
Interventions
L608Drug
Participants will receive L608 TID over 28 consecutive days.
PlaceboDrug
Participants will receive Placebo TID over 28 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to healing of the cardinal DUTime frame: up to 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.